Loading…
Develops precision small-molecule inhibitors targeting FGFR genetic alterations in cancer and genetic skeletal disorders.
Develops precision small-molecule inhibitors targeting FGFR genetic alterations in cancer and genetic skeletal disorders.
Has no product on the market, so no sales; it is funded by money raised from investors and spends it on clinical trials of its FGFR drugs. Its approach is to design drugs that keep working when cancer cells mutate to resist older ones. It went public in 2023.
Moat: none (IP / patents, process know-how). Proprietary structure-based platform designs FGFR inhibitors resistant to resistance mutations, but is clinical-stage.
Headquarters: Carlsbad, California, US · Founded: 2018 · Employees: 87
Size Tyra Bioscience (TYRA) is a United States Health Care company (Biotechnology) with a market value of $1.45B, the 2013th largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.15 on 6 Nov 2026.
Performance Over six months the shares fell 38.4%, against -18.7% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 18 in its peer set.
Short interest Short interest is 15.9% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$539,000 | -$546,000 | -$519,000 | -$353,000 | -$296,000 |
| EBITDA | -$160M | -$132M | -$104M | -$79.6M | -$58.6M |
| Net income | -$149M | -$120M | -$86.5M | -$69.1M | -$55.3M |
| Free cash flow | -$110M | -$95.3M | -$70.4M | -$50.9M | -$50.8M |
| Capital expenditure | $250,000 | $141,000 | $664,000 | $770,000 | $559,000 |
| Total debt | $5.58M | $5.81M | $6.22M | $6.50M | $2.62M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tyra Bioscience TYRA | $1.45B | -38% | n/a | n/a | n/a | n/a |
| BridgeBio Pharma BBIO | $14.5B | +10% | +167% | -37% | 18.3× | n/a |
| Incyte INCY | $24.4B | +21% | +25% | 12% | 3.4× | 14.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TYRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.9% | -5.0% | 5th highest of 21 |
| 6-month return | -38.4% | -18.7% | 3rd lowest of 18 |
| Distance from 52-week high | -48.0% | -40.7% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |